Document Detail

Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients.
MedLine Citation:
PMID:  11786115     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: It is thought that transforming growth factor-beta1 (TGF-beta1) might be a key inhibitor of atherogenesis in non-uremic patients. We evaluated the intra- and post-dialytic serum levels of TGF-beta1 in uremic patients to assess if TGF-beta1 is an independent risk factor for cardiovascular diseases, and if any correlation exists between TGF-beta1 and any yet known atherosclerotic risk factors. METHODS: We studied 155 patients who were on regular hemodialysis, with or without clinically significant atherosclerotic vascular disease. Forty-one apparently healthy people were enrolled as a control group. TGF-beta1 was evaluated during the midweek dialysis session, at times 0, 30, and 120 minues, at the end of the session, and 3 hours after the session's end. All hitherto known atherosclerotic risk factors also were evaluated. The investigation was performed over a 24-month follow-up. RESULTS: TGF-beta1 values (mean +/- SD) in dialysis patients were 26.64 +/- 7.0 ng/mL (N=155) compared with 42.31 +/- 6.0 ng/mL in the control group (N=41, P < 0.0001). A weak inverse correlation emerged between TGF-beta1 and age (r=-0.28), TGF-beta1 and lipoprotein(a) [Lp(a); r=-0.35], TGF-beta1 and C-reactive protein (CRP; r=-0.27), and TGF-beta1 and plasminogen activator inhibitor-1 (PAI-1; r=-0.41). TGF-beta1 also correlated with albumin (r=0.31). In the coronary heart disease (CHD) group (N=32) the TGF-beta1 was 26.2 +/- 4.9 ng/mL; in the cerebrovascular disease (CVD) group (N=8) it was 26.7 +/- 3.7 ng/mL and in the peripheral vascular disease (PVD) group (N=9) it was 25.4 +/- 1.7 ng/mL. In dialysis patients with no cardiovascular disease (N=80) TGF-beta1 was 35.1 +/- 6.8 ng/mL (P < 0.0001 vs. CHD, CVD and PVD patients). TGF-beta1 was significantly lower among those patients with triple coronary vessel disease than with the other CHD patients. The Cox analysis demonstrated that a 1 ng/mL reduction in TGF-beta1 concentration was associated with a 9% increase in the relative risk of a cardiovascular event. CONCLUSIONS: TGF-beta1 was significantly reduced in hemodialysis patients, in particular in those with severe cardiovascular disease. Baseline TGF-beta1, diabetes mellitus and serum albumin levels proved to be the only independent contributors to atherosclerotic risk in dialysis patients.
Sergio Stefoni; Giuseppe Cianciolo; Gabriele Donati; Ada Dormi; Maria Grazia Silvestri; Luigi Colì; Antonio De Pascalis; Sandra Iannelli
Related Documents :
18781605 - N-terminal pro-brain natriuretic peptide in the elderly with myocardial infarction.
1718285 - Human basophil releasability. viii. increased basophil releasability in patients with s...
16731165 - Clinical implication of blood levels of b-type natriuretic peptide in pediatric patient...
15110205 - Comparative accuracy of b-type natriuretic peptide and tissue doppler echocardiography ...
17223485 - Burn patient characteristics and outcomes following resuscitation with albumin.
3859395 - Philadelphia chromosome-positive chronic myelogenous leukemia following apparent acute ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Kidney international     Volume:  61     ISSN:  0085-2538     ISO Abbreviation:  Kidney Int.     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-01-11     Completed Date:  2002-03-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  324-35     Citation Subset:  IM    
Nephrology Dialysis and Renal Transplantation Unit, Department of Clinical Medicine and Applied Biotechnology, S. Orsola University Hospital, Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Coronary Artery Disease / blood*,  mortality*
Follow-Up Studies
Kidney Failure, Chronic / blood*,  mortality*,  therapy
Logistic Models
Middle Aged
Myocardial Ischemia / blood,  mortality
Predictive Value of Tests
Renal Dialysis
Risk Factors
Survival Analysis
Transforming Growth Factor beta / blood*,  genetics
Transforming Growth Factor beta1
Uremia / blood,  mortality,  therapy
Reg. No./Substance:
0/TGFB1 protein, human; 0/Transforming Growth Factor beta; 0/Transforming Growth Factor beta1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Urea volume of distribution exceeds total body water in patients with acute renal failure.
Next Document:  Quantifying porphobilinogen deaminase mRNA in microdissected nephron segments by a modified RT-PCR.